Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Reply to Comment: Is there any place for SGLT2-inhibitors in post-liver transplantation patients?

Pisano G, Donato F, Lombardi R, Dondossola D, Orsi E, Fracanzani AL.

Dig Liver Dis. 2020 Feb 13. pii: S1590-8658(20)30033-5. doi: 10.1016/j.dld.2020.01.007. [Epub ahead of print] No abstract available.

PMID:
32063500
2.

Prediction of hypertension, diabetes and fractures in eucortisolemic women by measuring parameters of cortisol milieu.

Morelli V, Aresta C, Gaudio A, Eller-Vainicher C, Zhukouskaya VV, Merlotti D, Orsi E, Maria Barbieri A, Fustinoni S, Polledri E, Gennari L, Falchetti A, Carnevale V, Persani L, Scillitani A, Chiodini I.

Endocrine. 2020 Jan 27. doi: 10.1007/s12020-020-02212-9. [Epub ahead of print]

PMID:
31989409
3.

Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment.

Orsi E, Bonora E, Solini A, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Zerbini G, Morano S, Nicolucci A, Penno G, Pugliese G.

J Clin Med. 2020 Jan 17;9(1). pii: E246. doi: 10.3390/jcm9010246.

4.

Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists.

Sciannameo V, Berchialla P, Orsi E, Lamacchia O, Morano S, Querci F, Consoli A, Avogaro A, Fadini GP; DARWIN-T2D study.

Diabetes Obes Metab. 2020 May;22(5):817-827. doi: 10.1111/dom.13962. Epub 2020 Feb 6.

PMID:
31943710
5.

Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes.

Lombardi R, Airaghi L, Targher G, Serviddio G, Maffi G, Mantovani A, Maffeis C, Colecchia A, Villani R, Rinaldi L, Orsi E, Pisano G, Adinolfi LE, Fargion S, Fracanzani AL.

Liver Int. 2020 Feb;40(2):347-354. doi: 10.1111/liv.14274. Epub 2019 Oct 31.

PMID:
31612634
6.

Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study.

Fadini GP, Li Volsi P, Devangelio E, Poli M, Cazzetta G, Felace G, Avogaro A; DARWIN-T2D Network.

J Endocrinol Invest. 2020 Mar;43(3):329-336. doi: 10.1007/s40618-019-01110-w. Epub 2019 Sep 12.

PMID:
31515744
7.

Cortisol Secretion, Sensitivity, and Activity Are Associated With Hypertension in Postmenopausal Eucortisolemic Women.

Chiodini I, Gaudio A, Eller-Vainicher C, Morelli V, Aresta C, Zhukouskaya VV, Merlotti D, Orsi E, Barbieri AM, Fustinoni S, Polledri E, Gennari L, Falchetti A, Carnevale V, Persani L, Scillitani A.

J Clin Endocrinol Metab. 2019 Oct 1;104(10):4441-4448. doi: 10.1210/jc.2019-00037.

PMID:
31112276
8.

Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study.

Solini A, Penno G, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Baroni MG, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.

BMC Med. 2019 Apr 25;17(1):83. doi: 10.1186/s12916-019-1313-x.

9.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

10.

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.

Fadini GP, Sciannameo V, Franzetti I, Bottigliengo D, D'Angelo P, Vinci C, Berchialla P, Arena S, Buzzetti R, Avogaro A; DARWIN-T2D network.

Diabetes Obes Metab. 2019 Aug;21(8):1886-1894. doi: 10.1111/dom.13747. Epub 2019 May 8.

11.

The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.

Meneghini LF, Mauricio D, Orsi E, Lalic NM, Cali AMG, Westerbacka J, Stella P, Candelas Dea C, Pilorget V, Perfetti R, Khunti K; DUNE investigators.

Diabetes Obes Metab. 2019 Jun;21(6):1429-1436. doi: 10.1111/dom.13673. Epub 2019 Mar 28.

12.

Management of diabetes mellitus in patients undergoing liver transplantation.

Grancini V, Resi V, Palmieri E, Pugliese G, Orsi E.

Pharmacol Res. 2019 Mar;141:556-573. doi: 10.1016/j.phrs.2019.01.042. Epub 2019 Jan 25. Review.

PMID:
30690071
13.

Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients.

Grancini V, Trombetta M, Lunati ME, Boselli ML, Gatti S, Donato MF, Palmieri E, Resi V, Pugliese G, Bonadonna RC, Orsi E.

J Hepatol. 2019 May;70(5):954-962. doi: 10.1016/j.jhep.2019.01.015. Epub 2019 Jan 21.

PMID:
30677460
14.

Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus.

Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, Dauriz M, Dotta F, Formichi C, Frontoni S, Invitti C, Orsi E, Picconi F, Resi V, Bonora E, Purrello F.

Acta Diabetol. 2019 Jun;56(6):605-617. doi: 10.1007/s00592-018-1271-3. Epub 2019 Jan 2. Review.

PMID:
30603867
15.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators.

Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.

PMID:
30291013
16.

Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study.

Fadini GP, Solini A, Manca ML, Zatti G, Karamouzis I, Di Benedetto A, Frittitta L, Avogaro A; DARWIN-T2D Network.

Acta Diabetol. 2018 Nov;55(11):1121-1129. doi: 10.1007/s00592-018-1194-z. Epub 2018 Aug 9.

PMID:
30090961
17.

Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study.

Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Scardapane M, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.

Diabetologia. 2018 Nov;61(11):2277-2289. doi: 10.1007/s00125-018-4691-2. Epub 2018 Jul 21.

PMID:
30032426
18.

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study.

Fadini GP, Bottigliengo D, D'Angelo F, Cavalot F, Bossi AC, Zatti G, Baldi I, Avogaro A; DARWIN-T2D Network.

Diabetes Ther. 2018 Aug;9(4):1477-1490. doi: 10.1007/s13300-018-0452-y. Epub 2018 Jun 1.

19.

Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes.

Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Morano S, Nicolucci A, Penno G, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group.

Diabetes Obes Metab. 2018 Aug;20(8):1885-1893. doi: 10.1111/dom.13306. Epub 2018 Apr 19.

PMID:
29582548
20.

Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.

Penno G, Solini A, Bonora E, Orsi E, Fondelli C, Zerbini G, Trevisan R, Vedovato M, Cavalot F, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group.

Acta Diabetol. 2018 Jun;55(6):603-612. doi: 10.1007/s00592-018-1133-z. Epub 2018 Mar 24.

PMID:
29574497

Supplemental Content

Loading ...
Support Center